Observed arrival · 2026-11-18
Beyond the Biobucks
A research series and data terminal tracking what happened after major Chinese pharmaceutical licensing deals were signed.
○Open
⊠Login
$Paid
†Ads
✦Pretty
●Pro
◎Niche
◉Human
⚑Risk
ƒJS
- For
- Readers tracking China–West pharmaceutical licensing deals
- Worth noticing
- Its dashboard reports 50 tracked deals and explicitly cautions that the comparisons are a small sample, not a statistical test.
Field notes
The terminal lets readers filter deals by therapeutic area, modality, status, and signing year, then inspect an asset’s stage and timeline since signing. It reports 50 tracked deals and labels 12 ended or cut back; its own note says the sample is small and has not been statistically tested. A rewind control compares the chart with information public on an earlier date, while leaving the deal reading current.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
○OpenPublic substance visible
✦PrettyNotable craft visible
●ProPolished or operationally mature
◎NicheUnusually specific use
One card from the complete issue